Effective May 26, 2020, tesamorelin for injection (Egrifta SVā¢) has been added to the ADAP formulary. Egrifta SVā¢ received U.S. Food and Drug Administration (FDA) approval on November 5, 2018 as a single-vial formulation. Egrifta SVā¢ is a growth hormone-releasing factor (GHRF) analog indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Lipodystrophy is defined as an abnormal distribution of fat tissue and can contribute to the development of fatty liver, dyslipidemia, and insulin resistance. Lipodystrophy in people living with HIV is often caused by exposure to certain older antiretroviral medications.
ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of Egrifta SVā¢. Access to the updated formulary is available at the following URL: https://cdph.magellanrx.com/member/documents.
If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.
Thank you,
Sandra Robinson, MBA
ADAP Branch Chief
California Department of Public Health